Cytosolix is a private, early stage life sciences company spun out of Yale University, developing novel oral & IV derivatives of known small molecule oncology drugs that selectively target cancer cells via a universal biomarker of solid tumors - acidity.

Cytosolix

Bioscience

Medical device

Connecticut Innovations provides strategic capital and operational insight to push the frontiers of high-tech industries such as energy, biotechnology, information technology, and photonics. Over the years, CI has helped over 100 emerging companies research, develop, and market new products and services. This activity has attracted over $1 billion dollars in additional investments from private equity providers. CI has brought the State of Connecticut over $510 million in Gross State Profit and over 5,000 additional job-years.

Career Opportunities